PMC:7195088 / 44088-44201 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7195088","sourcedb":"PMC","sourceid":"7195088","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7195088","text":"• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)","divisions":[{"label":"label","span":{"begin":0,"end":1}}],"tracks":[{"project":"LitCovid-PubTator","denotations":[{"id":"1207","span":{"begin":41,"end":49},"obj":"Species"}],"attributes":[{"id":"A1207","pred":"tao:has_database_id","subj":"1207","obj":"Tax:9606"},{"subj":"1207","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]},{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T74","span":{"begin":2,"end":10},"obj":"Body_part"},{"id":"T75","span":{"begin":72,"end":80},"obj":"Body_part"}],"attributes":[{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62871"},{"subj":"T74","pred":"source","obj":"LitCovid-PD-FMA-UBERON"},{"subj":"T75","pred":"source","obj":"LitCovid-PD-FMA-UBERON"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T347","span":{"begin":0,"end":113},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T347","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PubTator","color":"#aaec93","default":true},{"id":"LitCovid-PD-FMA-UBERON","color":"#ec93c4"},{"id":"LitCovid-sentences","color":"#93deec"}]}]}}